'Ann oncol' diaporamas de présentation

Optimal approach to medical management of synchronous colorectal liver metastases

MSO, School of Oncology. Optimal approach to medical management of synchronous colorectal liver metastases. Roma, 4 marzo 2011. Dott.ssa Angela Torsello. Angela TORSELLO Oncologia Medica A Istituto Regina Elena, Rom a. Colorectal cancer liver metastases. Colorectal cancer liver metastases.

973 views • 73 slides

Recherches internationales sur le Qi Gong

Recherches internationales sur le Qi Gong. Novembre 2013. 77 Medical Studies confirm the health benefits of Qigong and Tai Chi. Groundbreaking review of the "evidence base" for Qigong and Tai Chi The Most Comprehensive Review of the Health Benefits of Tai Chi and Qigong Published

852 views • 68 slides

OLD AND NEW ANTHACYCLINES: A STILL VALID OPTION IN BREAST CANCER TREATMENT True : Clara Natoli

OLD AND NEW ANTHACYCLINES: A STILL VALID OPTION IN BREAST CANCER TREATMENT True : Clara Natoli. Anthracyclines are actually the most discussed drugs in breast cancer treatment. Anthracyclines.

476 views • 40 slides

SOGUG meeting New drugs after docetaxel chemotherapy in patient with mCRPC

830 views • 38 slides

The Ethics of Cancer Research

The Ethics of Cancer Research. Laurie Lyckholm MD Virginia Commonwealth University Department of Internal Medicine Division of Hematology/Oncology. The Ethics of Cancer Research. Historical content Is there such a thing as informed consent?

444 views • 33 slides

The Ethics of Cancer Research

The Ethics of Cancer Research. Laurie Lyckholm MD Virginia Commonwealth University Department of Internal Medicine Division of Hematology/Oncology. The Ethics of Cancer Research. Historical content Is there such a thing as informed consent?

459 views • 33 slides

Adjuvant therapy of HER2 positive early breast cancer The Evidences

Adjuvant therapy of HER2 positive early breast cancer The Evidences. Antonio Frassoldati Oncologia Clinica - Ferrara. Evidences on adjuvant trastuzumab are based on randomized trials in over 14,000 women . S= sequential; C= concomitant

621 views • 27 slides

PET and Lymphoma

715 views • 26 slides

Grand Ward Round

582 views • 24 slides

LBA9094

LBA9094. The ultra-low-molecular-weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in cancer patients receiving chemotherapy: SAVE-ONCO study.

395 views • 19 slides

Learning Objectives A t the conclusion of this presentation participants should understand the following:

Use of pharmacogenetics in understanding patient susceptibility to 5-FU/capecitabine toxicity Toxicity risk associated with variations in DPYD and TYMS DPYD = DPD deficiency TYMS= TS deficiency Use of genetic test results in medical management.

546 views • 15 slides